Document text
Principal Investigator: David G Thanassi
Organization: STATE UNIVERSITY NEW YORK STONY BROOK
Fiscal Year: 2022
Award: $2,933,079
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY/ABSTRACT
The Laboratory for Comparative Medicine (LCM) at Stony Brook University is a recently constructed, state-of-
the-art animal biosafety level 3 (ABSL3) facility. The LCM is actively engaged in basic, translational, and
preclinical research on SARS-CoV-2, the viral agent of the current COVID-19 worldwide pandemic. Research
in the LCM serves multiple individual investigators and groups, both within and outside of Stony Brook
University, and includes commercial as well as academic interests. Stony Brook has a long history of
excellence in microbial pathogenesis research, including studies on pandemic potential viruses of concern in
the families Coronaviridae (SARS-CoV-2), Bunyavirales (Hantaviruses), Flaviviridae (Dengue, Zika, and
Powassan viruses), and Picornaviridae (Poliovirus). Stony Brook virologists are also conducting ongoing
studies in Human Immunodeficiency Virus and Influenza A Virus. Our research over the past five years has
covered three different RNA virus families relevant under the American Pandemic Preparedness/pandemic
preparedness effort, and our cumulative experience covers four of the viral families of concern. In addition to
viruses of concern, active research at Stony Brook and in the LCM includes work on the highly virulent
bacterial agents Rickettsia spp. of the spotted fever group, Francisella tularensis, a Select Agent and cause of
the zoonotic disease tularemia, and Mycobacterium tuberculosis, causative agent of tuberculosis. To improve
facility operations and enhance ongoing and future research in the LCM, we are requesting four upgrades to
the LCM: 1) Replacement of the high temperature hot water unfired steam boilers and conversion of the high
temperature and hot water systems; 2) Purchase and installation of a washer for animal cages and racks; 3)
Purchase and installation of a fluorescence-activated cell sorter and custom biosafety enclosure; and 4)
Acquisition of a real-time, quantitative reverse-transcription PCR machine. The requested upgrades will
support and improve pandemic preparedness-relevant research in the LCM, advance studies on highly virulent
and emerging pathogens, and provide enhanced resources not only to Stony Brook researchers, but also to
State and regional efforts to combat current and future pandemic threats. The requested improvements will
support the development of antiviral programs and antimicrobial preventive and therapeutic measures.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adenoviridae><Adenoviruses><Aerosols><American><Animal Model><Animal Models and Related Studies><Animals><Applied Research><Applied Science><Area><BSL-3 facility><BSL3 facility><Basic Research><Basic Science><Biologic Products><Biological Agent><Biological Products><Biotech><Biotechnology><Breakbone Fever Virus><Bunyavirales><COVID-19><COVID-19 therapeutics><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 therapeutics><COVID19 vaccine><COVID19 virus><CV-19><CV19><CoV-2><CoV2><Containment><Coronaviridae><Coronavirus><Custom><Dengue Virus><Dengue fever virus><Detection><Disease><Disorder><Duct><Duct (organ) structure><F tularensis><F tularensis infection><F. tularensis><F. tularensis infection><Faculty><Family><Family Picornaviridae><Flaviviridae><Francisella infection><Francisella tularensis><Francisella tularensis infection><Funding><Future><Gases><HIV><Hantavirus><High temperature of physical object><History><Human Immunodeficiency Viruses><Hydrogen Oxide><Immune mediated therapy><Immune response><Immunological response><Immunologically Directed Therapy><Immunotherapy><Individual><Infection><Influenza A><Influenza A virus><Influenza Viruses Type A><Influenzavirus A><Investigation><Investigators><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><M tb><M tuberculosis><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><Measures><Medicine><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><New York><Orthomyxovirus Type A><Pasteurella tularensis><Pathogenesis><Persons><Phase><Picornaviridae><Picornaviruses><Play><Plumbing><Population><Powassan><Powassan virus><Preventive><Process><Publications><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Viruses><RNA analysis><Recording of previous events><Research><Research Activity><Research Personnel><Research Resources><Researchers><Resources><Reverse Transcription><Rickettsia><Rickettsiales><Rodent><Rodentia><Rodents Mammals><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 therapeutics><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Security><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Steam><System><TB infection><Therapeutic><Time><Translational Research><Translational Science><Treatment Efficacy><Tuberculosis><Tularemia><Type A Influenza><Universities><Viral><Virulent><Virus><Virus-HIV><Water><Work><Wuhan coronavirus><ZIKV><Zika Virus><Zoonoses><Zoonotic><Zoonotic Infection><animal imaging><anti-microbial><anti-viral development><anti-viral drug development><anti-viral efficacy><anti-viral therapeutic development><anti-viral therapy development><antimicrobial><antiviral development><antiviral drug development><antiviral efficacy><antiviral therapeutic development><antiviral therapy development><bacteria pathogen><bacterial pathogen><biologics><biopharmaceutical><biosafety level 3 facility><biotherapeutic agent><combat><comparative><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 therapeutics><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><design><designing><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><disseminated TB><disseminated tuberculosis><emerging pathogen><equipment acquirement><equipment acquisition><equipment investment><equipment procurement><equipment purchase><equipment purchasing><exhaust><experience><flexibility><flexible><fluorescence activated cell sorter><fluorescence activated cell sorter device><fungal pathogen><fungi pathogen><hCoV19><heat exchanger><high temperature><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><improved><infected with F tularensis><infected with F. tularensis><infected with Francisella tularensis><infection due to Mycobacterium tuberculosis><infectious disease model><instrument acquisition><instrument investment><instrument procurement><instrument purchase><interest><intervention efficacy><metropolitan><microbe pathogen><microbial><microbial pathogen><model of animal><model organism><mtb><nCoV2><new pathogen><novel pathogen><operation><pandemic><pandemic disease><pandemic preparedness><pathogen><pathogenic bacteria><pathogenic fungus><pathogenic microbe><pathogenic virus><pre-clinical><pre-clinical research><preclinical><preclinical research><programs><qRTPCR><social role><spotted fever><therapeutic efficacy><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><therapy efficacy><tool><translation research><tuberculosis infection><tuberculous spondyloarthropathy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><viral pathogen><virology><virus pathogen><zikav>